Strong sales of cholesterol drugs helped Schering-Plough post a twofold increase in quarterly profit this week, but earnings may expose an over-reliance on Vytorin and Zetia.

Par Pharmaceutical reached a settlement and license agreement with Ortho-McNeil Pharmaceutical, ending a patent suit related to the Johnson Johnson units Ultracet acute pain product.

Three years after the FDA yanked its Wild Thing ads off the air, Pfizer is again taking a playful approach with a Viagra TV spot riffing on the Elvis hit Viva Las Vegas. And this time they got the agencys OK in advance.

Eli Lilly posted strong second-quarter sales results yesterday, despite a 19% net income drop due to charges and other items.

An estimated 14,000 patients across the globe are currently taking Elan and Biogen IDECs multiple sclerosis treatment Tysabri, a year after the drugs return to market.

Boehringer Ingelheims DTC campaign for Mirapex broke last week, days after scientists reported a genetic basis for restless leg syndrome, helping legitimize the disorder.

The second-quarter earnings parade today told a story of two companies, whose lipid franchises are heading in divergent directions.

PDI has inked a deal with an undisclosed top-five pharmaceutical company that is expected to generate $23 million in revenue for the contract sales firm over its one-year term.

The FDA has approved a new patch form of Novartis Alzheimers disease treatment Exelon (rivastigmine transdermal system), the drugmaker said Monday.

Your at-a-glance guide to which agencies hold the professional and consumer accounts on the top 20 prescription drug brands by US sales